ISUP Consensus Definition of Cribriform Pattern Prostate Cancer.


Journal

The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904

Informations de publication

Date de publication:
01 08 2021
Historique:
pubmed: 18 5 2021
medline: 25 9 2021
entrez: 17 5 2021
Statut: ppublish

Résumé

The presence of a cribriform pattern is now recognized as a clinically important, independent adverse prognostic indicator for prostate cancer. For this reason the International Society of Urological Pathology (ISUP) recently recommended its inclusion in standard reporting. In order to improve interobserver agreement as to the diagnosis of cribriform patterns, the ISUP assembled an international panel of 12 expert urogenital pathologists for the purpose of drafting a consensus definition of cribriform pattern in prostate cancer, and provide their opinions on a set of 32 images and on potential diagnostic criteria. These images were selected by the 2 nonvoting convenors of the study and included the main categories where disagreement was anticipated. The Delphi method was applied to promote consensus among the 12 panelists in their review of the images during 2 initial rounds of the study. Following a virtual meeting, convened to discuss selected images and diagnostic criteria, the following definition for cribriform pattern in prostate cancer was approved: "A confluent sheet of contiguous malignant epithelial cells with multiple glandular lumina that are easily visible at low power (objective magnification ×10). There should be no intervening stroma or mucin separating individual or fused glandular structures" together with a set of explanatory notes. We believe this consensus definition to be practical and that it will facilitate reproducible recognition and reporting of this clinically important pattern commonly seen in prostate cancer. The images and the results of the final Delphi round are available at the ISUP website as an educational slide set (https://isupweb.org/isup/blog/slideshow/cribriform-slide-deck/).

Identifiants

pubmed: 33999555
doi: 10.1097/PAS.0000000000001728
pii: 00000478-202108000-00011
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1118-1126

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Références

Epstein JI, Egevad L, Amin MB, et al. Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244–252.
Iczkowski KA, Paner GP, Van der Kwast T. The new realization about cribriform prostate cancer. Adv Anat Pathol. 2018;25:31–37.
Kweldam CF, van der Kwast T, van Leenders GJ. On cribriform prostate cancer. Transl Androl Urol. 2018;7:145–154.
Keefe DT, Schieda N, El Hallani S, et al. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3+4=7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy. Virchows Arch. 2015;467:437–442.
Kweldam CF, Kümmerlin IP, Nieboer D, et al. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy. Mod Pathol. 2016;29:630–636.
Van Leenders GJLH, Kweldam, CF, Hollemans E, et al. Improved Prostate Cancer Biopsy Grading by incorporation of invasive cribriform and intraductal carcinoma in the 2014 grade groups. Eur Urol. 2020;77:191–198.
Tom MC, Nguyen JK, Lucianò R, et al. Impact of cribriform pattern and intraductal carcinoma on Gleason 7 prostate cancer treated with external beam radiotherapy. J Urol. 2019;202:710–716.
Ericson KJ, Wu SS, Lundy SD, et al. Diagnostic accuracy of prostate biopsy for detecting cribriform Gleason pattern 4 carcinoma and intraductal carcinoma in paired radical prostatectomy specimens: implications for active surveillance. J Urol. 2020;203:311–319.
van Leenders GJLH, van der Kwast TH, Grignon DJ, et al. ISUP Grading Workshop Panel Members. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020;44:e87–e99.
Mottet N, Bellmunt J, Briers E, et al.; Members of the EAU—ESTRO—ESUR—SIOG Prostate Cancer Guidelines Panel. EAU—ESTRO—ESUR—SIOG Guidelines on Prostate Cancer. Edn. Presented at the EAU Annual Congress Amsterdam 2020. 978-94-92671-07-3. Arnhem, The Netherlands: EAU Guidelines Office.
Verhoef EI, van Cappellen WA, Slotman JA, et al. Three-dimensional analysis reveals two major architectural subgroups of prostate cancer growth patterns. Mod Pathol. 2019;32:1032–1041.
Kweldam CF, Nieboer D, Algaba F, et al. Gleason grade 4 prostate adenocarcinoma patterns: an interobserver agreement study among genitourinary pathologists. Histopathology. 2016;69:441–449.
Kleynen M, Braun SM, Bleijlevens MH, et al. Using a Delphi technique to seek consensus regarding definitions, descriptions and classification of terms related to implicit and explicit forms of motor learning. PLoS ONE. 2014;9:e100227.
Samaratunga H, Delahunt B, Srigley JR, et al. Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases. Histopathology. 2017;71:641–647.
Iczkowski KA, Torkko KC, Kotnis GR, et al. Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol. 2011;136:98–107.
Kweldam CF, van Leenders GJ, van der Kwast T. Grading of prostate cancer: a work in progress. Histopathology. 2019;74:146–160.
Van Leenders GJLH, Verhoef EI, Hollemans E. Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading. Histopathology. 2020;77:850–861.
Hollemans E, Verhoef EI, Bangma CH, et al. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. Mod Pathol. 2019;32:139–146.
Masoomian M, Downes MR, Sweet J, et al. Concordance of biopsy and prostatectomy diagnosis of intraductal and cribriform carcinoma in a prospectively collected data set. Histopathology. 2019;74:474–482.
Hollemans E, Verhoef EI, Bangma CH, et al. Concordance of cribriform architecture in matched prostate cancer biopsy and radical prostatectomy specimens. Histopathology. 2019;75:338–345.
Mori S, Chang J, Andrechek E, et al. Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene. 2009;28:2796–2805.
Lotan TL, Epstein JI. Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Hum Pathol. 2009;40:471–477.
Tolkach Y, Kristiansen G. Cribriform and glomeruloid acinar adenocarcinoma of the prostate-an intratumoral intraductal carcinoma? Histopathology. 2019;74:804–808.
Choy B, Pearce SM, Anderson BB, et al. Prognostic significance of percentage and architectural types of contemporary Gleason pattern 4 prostate cancer in radical prostatectomy. Am J Surg Pathol. 2016;40:1400–1406.
Kweldam CF, Wildhagen MF, Steyerberg EW, et al. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol. 2015;28:457–464.
Hollemans E, Verhoef EI, Bangma CH, et al. Clinicopathological characteristics of glomeruloid architecture in prostate cancer. Mod Pathol. 2020;33:1618–1625.
Epstein JI, Allsbrook WC Jr, Amin MB, et al. ISUP Grading Committee. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29:1228–1242.
Osunkoya AO, Nielsen ME, Epstein JI. Prognosis of mucinous adenocarcinoma of the prostate treated by radical prostatectomy: a study of 47 cases. Am J Surg Pathol. 2008;32:468–472.
Lane BR, Magi-Galluzzi C, Reuther AM, et al. Mucinous adenocarcinoma of the prostate does not confer poor prognosis. Urology. 2006;68:825–830.
Prendeville S, Nesbitt ME, Evans AJ, et al. Variant histology and clinicopathological features of prostate cancer in men younger than 50 years treated with radical prostatectomy. J Urol. 2017;198:79–85.
McKenney JK, Wei W, Hawley S, et al. Histologic grading of prostatic adenocarcinoma can be further optimized: analysis of the relative prognostic strength of individual architectural patterns in 1275 patients from the Canary retrospective cohort. Am J Surg Pathol. 2016;40:1439–1456.

Auteurs

Theodorus H van der Kwast (TH)

Department of Pathology, Princess Margaret Cancer Center, University Health Network.

Geert J van Leenders (GJ)

Department of Pathology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.

Daniel M Berney (DM)

Barts Health NHS Trust, London.

Brett Delahunt (B)

Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.

Andrew J Evans (AJ)

Department of Pathology, Princess Margaret Cancer Center, University Health Network.

Kenneth A Iczkowski (KA)

Department of Pathology, Medical College of Wisconsin, Milwaukee, WI.

Jesse K McKenney (JK)

Department of Pathology, Cleveland Clinic, Cleveland, OH.

Jae Y Ro (JY)

Department of Pathology, Medical College of Wisconsin, Milwaukee, WI.

Hemamali Samaratunga (H)

Department of Pathology, University of Queensland School of Medicine, and Aquesta Uropathology, Queensland, Australia.

John R Srigley (JR)

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.

Toyo Tsuzuki (T)

Department of Pathology and Surgical Pathology, Aichi Medical University, Japanese Red Cross Nagoya Daini Hospital, Japan.

Murali Varma (M)

Department of Pathology, Cardiff, Wales, UK.

Thomas M Wheeler (TM)

Department of Pathology, Baylor College of Medicine, Houston, TX.

Lars Egevad (L)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH